NO and NO-independent mechanisms mediate ETB receptor buffering of ET-1-induced renal vasoconstriction in the rat

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 288, Issue 5 57-5, 2005, Pages

  Just, Armin ^a,c   Olson, Andrea J M ^a   Falck, John R ^b   Arendshorst, William J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Cyclooxygenase; Dopamine; Endothelial cell; Endothelin; Epoxygenase; Nitric oxide; Renal hemodynamics

Indexed keywords

ANGIOTENSIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENZYME; EPOXYGENASE; EPOXYICOSATETRAENOIC ACID; FENOLDOPAM; INDOMETACIN; MESYLIC ACID DERIVATIVE; METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL)HEXANAMIDE; MICONAZOLE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PROSTAGLANDIN SYNTHASE; PROSTANOID; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; ENZYME INHIBITION; KIDNEY BLOOD FLOW; MALE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CYCLOOXYGENASE INHIBITORS; ENDOTHELIN-1; KIDNEY; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLIGOPEPTIDES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN B; RENAL CIRCULATION; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 17844384204     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00550.2004     Document Type: Article

References (47)

1. Agapitov AV and Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 3: 1-15, 2002.
2. Beierwaltes WH, Sigmon DH, and Carretero OA. Endothelium modulates renal blood flow but not autoregulation. Am J Physiol Renal Fluid Electrolyte Physiol 262: F943-F949, 1992.
3. B receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension 36: 1002-1007, 2000.
4. Bhowmick N, Narayan P, and Puett D. The endothelin subtype A receptor undergoes agonist- and antagonist-mediated internalization in the absence of signaling. Endocrinology 139: 3185-3192, 1998.
5. B receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 104: 143-151, 2003.
6. Bousette N and Giaid A. Endothelin-1 in atherosclerosis and other vasculopathies. Can J Physiol Pharmacol 81: 578-587, 2003.
7. Brand-Schieber E, Falck JF, and Schwartzman M. Selective inhibition of arachidonic acid epoxidation in vivo. J Physiol Pharmacol 51: 655-672, 2000.
8. Chatziantoniou C and Arendshorst WJ. Impaired ability of prostaglandins to buffer renal vasoconstriction in genetically hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 263: F573-F580, 1992.
9. ω-nitro-L- arginine methyl ester on arterial pressure and on vasodilator and vasoconstrictor responses: influence of initial vascular tone. Eur J Pharmacol 212: 159-164, 1992.
10. B receptor antagonist, BQ-788. Br J Pharmacol 113: 1257-1262, 1994.
11. Duke PC and Trosky S. The effect of halothane with nitrous oxide on baroreflex control of heart rate in man. Can Anaesth Soc J 27: 531-534, 1980.
12. Fellner SK and Arendshorst WJ. Endothelin A and B receptors of preglomerular vascular smooth muscle cells. Kidney Int 65: 1810-1817, 2004.
13. Filep JG, Battistini B, Cote YP, Beaudoin AR, and Sirois P. Endothelin-1 induces prostacyclin release from bovine aortic endothelial cells. Biochem Biophys Res Commun 177: 171-176, 1991.
14. B receptors in rats. Biochem Biophys Res Commun 199: 1461-1465, 1994.
15. Gellai M, De Wolf R, Fletcher T, and Nambi P. Contribution of endogenous endothelin-1 to the maintenance of vascular tone: role of nitric oxide. Pharmacology 55: 299-308, 1997.
16. Gellai M, DeWolf R, Pullen M, and Nambi P. Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int 46: 1287-1294, 1994.
17. Gellai M, Fletcher T, Pullen M, and Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol Regul Integr Comp Physiol 271: R254-R261, 1996.
18. Haynes WG and Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098, 1998.
19. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, and Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367-1373, 1993.
20. Hirata Y, Hayakawa H, Suzuki E, Kimura K, Kikuchi K, Nagano T, Hirobe M, and Omata M. Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation 91: 1229-1235, 1995.
21. Ikenaga H, Fallet RW, and Carmines PK. Basal nitric oxide production curtails arteriolar vasoconstrictor responses to ANG II in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 271: F365-F373, 1996.
22. Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, and Inscho EW. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension 35: 307-312, 2000.
23. 2 interactions in spontaneously hypertensive rats. Hypertension 22: 688-698, 1993.
24. A receptors. Am J Physiol Renal Physiol 286: F660-F668, 2004.
25. G-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol 103: 1321-1326, 1991.
26. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, Selwyn AP, and Ganz P. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 104: 1114-1118, 2001.
27. B receptors. J Cardiovasc Pharmacol 39: 533-543, 2002.
28. MacLean MR, Graham J, and McGrath JC. Endogenous nitric oxide modulates vasopressor responses, but not depressor responses, to spinal sympathetic nerve stimulation in pithed rats. J Cardiovasc Pharmacol 23: 319-325, 1994.
29. Madeddu P, Anania V, Parpaglia PP, Troffa C, Pazzola A, Soro A, Manunta P, Tonolo G, Dementis MP, and Varoni MV. Endothelin-1-induced renal vasoconstriction is blunted by enalaprilat and enhanced by EDRF antagonist in awake normotensive rats. Clin Invest Med 14: 600-606, 1991.
30. Marshall JL and Johns EJ. Influence of endothelins and sarafotoxin 6c and L-NAME on renal vasoconstriction in the anaesthetized rat. Br J Pharmacol 128: 809-815, 1999.
31. Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, Opgenorth TJ, Gariepy CE, and Yanagisawa M. Increased susceptibility to deoxycorticosterone acetate-salt-induced hypertension in endothelin-B-receptor- deficient rats. J Cardiovasc Pharmacol 36: S86-S89, 2000.
32. Matsuura T, Miura K, Ebara T, Yukimura T, Yamanaka S, Kim S, and Iwao H. Renal vascular effects of the selective endothelin receptor antagonists in anaesthetized rats. Br J Pharmacol 122: 81-86, 1997.
33. Messer Letienne I, Bernard N, Roman RJ, Sassard J, and Benzoni D. Cytochrome P-450 arachidonate metabolite inhibition improves renal function in Lyon hypertensive rats. Am J Hypertens 12: 398-404, 1999.
34. Navar LG, Inscho EW, Majid DSA, Imig JD, Harrison Bernard LM, and Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 76: 425-536, 1996.
35. Neylon CB. Vascular biology of endothelin signal transduction. Clin Exp Pharmacol Physiol 26: 149-153, 1999.
36. Nichols AJ, Ruffolo RR Jr, and Brooks DP. The pharmacology of fenoldopam. Am J Hypertens 3: 116S-119S, 1990.
37. Parekh N, Dobrowolski L, Zou AP, and Steinhausen M. Nitric oxide modulates angiotensin II- and norepinephrine-dependent vasoconstriction in rat kidney. Am J Physiol Regul Integr Comp Physiol 270: R630-R635, 1996.
38. Piel G, Evrard B, Van Hees T, and Delattre L. Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution. Int J Pharm 180: 41-45, 1999.
39. A receptors. Am J Physiol Heart Circ Physiol 283: H1555-H1561, 2002.
40. Roberts-Thomson P, McRitchie RJ, and Chalmers JP. Endothelin-1 produces heterogeneous regional haemodynamic effects in conscious rabbits. Clin Exp Hypertens 18: 145-169, 1996.
41. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002.
42. 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun 167: 1191-1195, 1990.
43. Tsoukias NM and Popel AS. A model of nitric oxide capillary exchange. Microcirculation 10: 479-495, 2003.
44. B receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 269: 21778-21785, 1994.
45. Wang QD, Li XS, and Pernow J. Characterization of endothelin-1-induced vascular effects in the rat heart by using endothelin receptor antagonists. Eur J Pharmacol 271: 25-30, 1994.
46. G-nitro-L-arginine by halothane. J Cardiovasc Pharmacol 22: 571-578, 1993.
47. Yukimura T, Notoya M, Mizojiri K, Mizuhira V, Matsuura T, Ebara T, Miura K, Kim S, Iwao H, and Song K. High-resolution localization of endothelin receptors in rat renal medulla. Kidney Int 50: 135-147, 1996.